急性冠脉综合征的药物基因组学研究进展  

The Role of Pharmacogenomics in the Personalized Treatment for Acute Coronary Syndrome

作　　者：张伟丽[1] 宋雷[2] 陈宇[1] 刘继斌[1] 吴永健[3] 惠汝太 

机构地区：[1]中国医学科学院北京协和医学院阜外心血管病医院心血管病相关基因与临床研究教育部重点实验室(中德分子医学研究室),北京市100037 [2]中国医学科学院北京协和医学院阜外心血管病医院高血压诊治中心,北京市100037 [3]中国医学科学院北京协和医学院阜外心血管病医院冠心病诊治中心,北京市100037

出　　处：《中国分子心脏病学杂志》2011年第4期251-256,共6页Molecular Cardiology of China

基　　金：国家自然科学基金 (81070172);国家973重点基础研究发展规划基金 (2011CB503901)

摘　　要：不同患者对许多心血管病药物的治疗效果和不良反应存在较大差异。患者的生理状态(如年龄、性别、种族、肥胖、高血压、糖尿病等)、环境危险因素(如吸烟、饮酒)、以及遗传多态性是产生个体差异的重要原因。药物基因组学(pharmacogenomics)的目标是发现这些影响药物反应的遗传因素,阐明不同个体的药物反应(有效性和不良反应)差异,最终针对个体基因型指导个体化用药。本文对急性冠脉综合征治疗药物(包括抗血小板药物、纤溶剂、抗凝剂、β阻滞剂)的药物基因组学研究进展进行综述,并总结了目前研究的局限性及发展方向。The pharmacologic treatment of acute coronary syndrome (ACS) need to use multiple classes of medication with the aim of reducing major cardiovascular events, but the intersubject variability in the efficacy and adverse drug reactions (ADRs) exits. The clinical characteristics of patients (such as age, gender, race, obese, hypertension, and diabetes) and environmental risk factors (such as smoking and alcohol use) affect the drug efficacy and safety. Emerging evidence showed that genetic factors may significantly contribute to the individual variability observed in the response to ACS pharmacotherapy. The field of pharmacogenomics aims to discover these genetic determinants to identify individuals who are most likely to respond, experience an ADR, or benefit from an alternative dosing regimen for a given drug, and may eventually provide guidance to the optimized pharmacotherapy for ACS. In this review, we summarized the pharmacogenomic data related to cardiovascular drug efficacy and toxicity, including antiplatelet agents, anticoagulants, fibrinolytics, beta blockers, and neurohormonal inhibitors.

关 键 词：药物基因组学 急性冠脉综合征 遗传多态 个体化医疗模式 

分 类 号：R541.4[医药卫生—心血管疾病]